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Whilst inﬂuence induced by bacterial colonization in cystic ﬁbrosis (CF) is estab-
lished, prevalence of Aspergillus fumigatus, or other species and factors associated
with fungal presence is poorly documented.
Our prospective study aimed to determine which fungal species are present in
sputum from CF patients, and which factors are associated with this presence.
The fungal risk was determined according: (i) clinical data, (ii) treatment used
(including antibiotics, corticosteroids and antifungal treatments), (iii) fungal pres-
ence in sputum using semi-selective growing media according to a unique and
standardised protocol of Mycology, and (iv) blood analysis to document patient
ABPA status.
300 CF patients have been included and will be followed-up during the next 2 years.
The majority were adults with a median age of 28.1 years. The average age in our
Paediatric population was 12.8 years old. Aspergillus fumigatus was found in about
30% of patients, with a decreased in vitro sensitivity to azoles in 10 to 15% cases.
Correlation between fungal, clinical, environmental, therapeutic or microbiological
data is evaluated.
Since fungal presence in CF appears frequent, inﬂuence of fungal presence on CF
course will be characterised. The 2 years follow-up will allow us to expect a better
understanding of ﬁlamentous fungus role in CF course, and to establish if patients
could beneﬁt from antifungal treatments or preventive measures.
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Background: The incidence of ITZ resistance in Af is increasing in the Nether-
lands. In a small CFcenter (n = 70) we identiﬁed 4 patients with ITZ resistant Af .
It is unclear how resistance develops and if risk factors can be identiﬁed.
Aim: To identify possible factors associated with the occurrence of ITZ resistant Af .
Methods: We describe baseline characteristics, clinical conditions and medication
use of 4 CF patients with ITZ resistant Af .
Results: Case 1 is a male (unknown CFTR) born in 1960 who died in 2006.
He was known with liver disease and Pseudomonas (Ps.) colonization. In 2002,
allergic bronchopulmonary aspergillosis (ABPA) was assessed. ITZ and prednisolon
(PRED) resulted in a remission despite ITZ resistant Af . ABPA relapsed in the
following years. In 2006, still using ITZ and PRED, an ITZ sensitive Af was
found. Case 2 is a female (dF508/dF508) with CF Related Diabetes (CFRD), liver
cirrhosis, renal disease and Ps. colonization. First ITZ resistant Af was found in
2004. A probable ABPA led to a successful trial of ITZ and PRED. Only ITZ
sensitive Af was found thereafter. She died in 2007 (age 34). Case 3 is a female born
in 1974 (dF508/dF508), known with CFRD and colonized with Ps. and episodes
of ITZ resistant or sensitive Af . Case 4 is a woman born in 1991 (dF508/dF508),
diagnosed with ABPA and Ps. colonization. Both ITZ resistant and sensitive Af were
found during ITZ and PRED use. She had a successful lung transplant in 2006.
ITZ resistant Af was more frequent during hospitalization although sampling
frequency was irregular.
Conclusion: ITZ resistant Af may be found in CF patients. No speciﬁc clinical
factors associated with their occurrence were found.
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Introduction: Since 1995, the reported incidence and diversity of fungi as lung
pathogens in Cystic Fibrosis (CF) has increased. There is emerging evidence
that fungi may cause infection but hypersensitivity remains the most common
manifestation. This study set out to establish the frequency of fungal atopy in
an adult CF cohort.
Methods: 46 patients at the Manchester Adult CF Unit underwent immediate
hypersensitivity skin prick testing (SPT) to 5 fungal allergens and 5 common
allergens. Wheals 3mm after 15 minutes were considered positive. Blood was
taken for total IgE and fungal speciﬁc IgEs by UniCap immunoassay (class 1 is
consistent with atopy and >2 with allergic bronchopulmonary mycosis (ABPM)).
Results: 76% of patients demonstrated a class 1 speciﬁc IgE response to 1
or more fungal allergens. Aspergillus fumigatus 67%, Alternaria alternata 30%,
Cladosporium herbarum, 15%, Candida albicans 15%, Penicillium notatum 48%.
SPT had similar results: A.fumigatus 74%, A.alternata 19%, C.herbarum 14%,
C.albicans 28%, P.notatum 37%. 19 (46%) patients demonstrated a >Class 2
response to 1 or more fungal allergens. Fungal atopy was more common in patients
with atopy to common allergens. 32 (70%) patients demonstrated positive SPT to
1 or more common allergens. Of those with no positive SPT to common allergens,
27% had fungal atopy whereas of those with positive SPT 68% demonstrated fungal
atopy. Total IgE was also associated with fungal atopy. Patients with an IgE> 500
demonstrated on average 4 out of 5 positive reactions. Patients with an IgE< 500
demonstrated on average 1 out of 5 positive reactions.
Conclusion: Fungal atopy is common in adult CF. There is a high percentage at
risk of ABPM. More research into the clinical relevance of this is required.
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Aim: Because of its controlling and modulating features, the intestinal microbiota
plays a key role in the development and homeostasis of the host immune system.
External factors, such as multiple high-dose antibiotic treatment courses in cystic
ﬁbrosis (CF) patients, may trigger dysbiosis in the gut and therefore contribute to
several disorders. This study aims to compare the diversity of predominant members
of the fecal microbiota in a group of CF patients with these of healthy siblings.
Methods: One general medium for colon bacteria and six selective media were
used for cultivation and enumeration of a selection of predominant groups (En-
terobacteriaceae, lactic acid bacteria, clostridia, biﬁdobacteria, Veillonella spp.
and Bacteroides & Prevotella spp., resp.). In addition, population proﬁling of the
microbial community was performed with denaturing gradient gel electrophoresis
(DGGE) using V3−16S rRNA gene primers.
Results and Discussion: For most of the culture media included, plate counts
were generally higher for samples of healthy siblings (n = 15) compared to CF
samples (n = 19). Preliminary analysis of DGGE ﬁngerprints revealed highly com-
plex microbial communities in both groups. In some cases, DGGE proﬁles of
the CF patient and his sibling differed in complexity, whereas in other pairs the
corresponding proﬁles were relatively similar. For some patients, DGGE proﬁle
complexity from two sampling points remained virtually unchanged, whereas for
other patients DGGE proﬁles indicated temporal instability between subsequent time
points. These observations will be conﬁrmed as more samples will be included and
culturing and DGGE data will be analyzed in more depth.
